Treeline Biosciences, a stealth-mode startup founded by former Loxo Oncology CEO Josh Bilenker, is pursuing a reverse merger with Standard Biotools. The deal would take the privately held cancer drug developer public without a traditional IPO.
The company has a trio of cancer drugs currently in early-stage clinical testing, with additional candidates following closely behind in preclinical development. Specific drug targets, mechanisms, and trial data have not been disclosed.
This reverse merger provides a faster, less regulated path to public markets compared to an initial public offering. Standard Biotools, the merger partner, is a publicly traded life sciences tools company, though the combined entity's name and leadership structure remain unclear.
For Treeline, the move signals increasing confidence in its pipeline and a desire to access deeper capital markets. The startup has raised significant venture funding but has remained largely under the radar, making this one of its first major public disclosures.
However, the strategy carries risks. Reverse mergers often face heightened regulatory and investor scrutiny, and early-stage cancer drugs carry high failure rates in clinical trials. The merger's success hinges on Treeline's ability to advance its pipeline and generate positive data.